Compare UL & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UL | GSK |
|---|---|---|
| Founded | 1930 | 1715 |
| Country | United Kingdom | United Kingdom |
| Employees | 96092 | 66841 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.3B | 108.7B |
| IPO Year | N/A | N/A |
| Metric | UL | GSK |
|---|---|---|
| Price | $57.33 | $51.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.7M | ★ 3.9M |
| Earning Date | 03-12-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.04% | 3.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.53 | $6.99 |
| Revenue Next Year | $3.78 | $4.19 |
| P/E Ratio | ★ $14.29 | $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.95 | $35.45 |
| 52 Week High | $74.98 | $61.70 |
| Indicator | UL | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 44.83 |
| Support Level | $56.64 | $48.99 |
| Resistance Level | $61.14 | $51.46 |
| Average True Range (ATR) | 0.79 | 0.77 |
| MACD | 0.07 | 0.22 |
| Stochastic Oscillator | 29.77 | 81.99 |
Unilever is a diversified beauty, wellbeing, and personal care (51% of 2025 sales by value), homecare (23%), and packaged food (26%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.